FrancophonIA/ELRC3.0 huggingface dataset:
English: Trough levels of 5-10% have been targeted in clinical trials for achieving bleeding control while on prophylaxis.
Estonian: Profülaktika aegset veritsuskontrolli saavutamist puudutavates kliinilistes uuringutes olid minimaalsed sihtväärtused 5…10%.
English: CSL Behring GmbH Emil-von-Behring Strasse 76 35041 Marburg Germany
Estonian: CSL Behring GmbH Emil-von-Behring Strasse 76 35041 Marburg Saksamaa
English: Activated factor IX, in combination with activated factor VIII, activates factor X. This results ultimately in the conversion of prothrombin to thrombin.
Estonian: Aktiveeritud IX faktor aktiveerib koos aktiveeritud VIII faktoriga X faktori.
English: For routine prophylaxis the recommended dose regimen for paediatric subjects is 35 to 50 IU/kg once weekly.
Estonian: Lapsed Rutiinseks profülaktikaks soovitatav annustamisskeem lastel on 35…50 RÜ/kg üks kord nädalas.
English: IDELVION 2000 IU powder and solvent for solution for injection 1 vial with powder
Estonian: IDELVION 2000 RÜ süstelahuse pulber ja lahusti: 1 viaal pulbriga
English: IDELVION 2000 IU powder and solvent for solution for injection Powder (2000 IU) in a 10 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Estonian: Pulber (2000 RÜ) 10 ml viaalis (I tüüpi klaas), millel on punnkork (kummist), kate (plastist) ja ümbris (alumiiniumist).
English: Albutrepenonacog alfa 500 IU
Estonian: Alfaalbutrepenonakog 500 RÜ
English: 2.5 ml of solvent in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Estonian: 2,5 ml lahusti viaalis (I tüüpi klaas), millel on punnkork (kummist), kate (plastist) ja ümbris (alumiiniumist).
English: IDELVION 250 IU powder and solvent for solution for injection: 1 vial with powder
Estonian: IDELVION 250 RÜ süstelahuse pulber ja lahusti: 1 viaal pulbriga
English: IDELVION 500 IU powder and solvent for solution for injection 260 - 300 mOsm/kg.
Estonian: IDELVION 500 RÜ süstelahuse pulber ja lahusti 260…300 mOsm/kg.
English: - Do not use solutions that are cloudy or have deposits.
Estonian: - Mitte kasutada hägust või sadet sisaldavat lahust.
English: For an incremental recovery of 1.3 IU/dl per 1 IU/kg, the dose is calculated as follows: Dose (IU) = body weight (kg) x desired factor IX increase (IU/dl) x 0.77 dl/kg
Estonian: Annus (RÜ) = kehamass (kg) x soovitud IX faktori sisalduse suurenemine (RÜ/dl) x 0,77 dl/kg
English: 5 ml of solvent in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Estonian: 5 ml lahusti viaalis (I tüüpi klaas), millel on punnkork (kummist), kate (plastist) ja ümbris (alumiiniumist).
English: Open the Mix2Vial by peeling off the lid. Do not remove the Mix2Vial from the blister package!
Estonian: Ärge võtke Mix2Viali blisterpakendist välja!
English: IDELVION 250 IU powder and solvent for solution for injection One vial contains nominally 250 IU of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP), (INN = albutrepenonacog alfa).
Estonian: Üks viaal sisaldab nominaalselt 250 RÜ IX faktorit albumiiniga ühendavat rekombinantset liitvalku (rIX FP) (INN = alfaalbutrepenonakog).
English: 1 disposable 10 ml syringe 1 venipuncture set 2 alcohol swabs
Estonian: 1 ühekordne 10 ml süstal 1 veenipunktsiooni komplekt 2 alkoholiga immutatud vatitampooni 1 mittesteriilne plaaster
English: IDELVION 250 IU powder and solvent for solution for injection Powder (250 IU) in a 6 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Estonian: Pulber (250 RÜ) 6 ml viaalis (I tüüpi klaas), millel on punnkork (kummist), kate (plastist) ja ümbris (alumiiniumist).
English: IDELVION 2000 IU powder and solvent for solution for injection One vial contains nominally 2000 IU of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP), (INN = albutrepenonacog alfa).
Estonian: Üks viaal sisaldab nominaalselt 2000 RÜ IX faktorit albumiiniga ühendavat rekombinantset liitvalku (rIX FP) (INN = alfaalbutrepenonakog).
English: 2000 IU per vial; after reconstitution with 5 ml of water for injections the solution contains 400 IU/ml of albutrepenonacog alfa.
Estonian: 2000 RÜ viaali kohta; pärast manustamiskõlblikuks muutmist 5 ml süsteveega sisaldab lahus 400 RÜ/ml alfaalbutrepenonakogi.
English: powder and solvent for solution for injection 1 vial with powder: 250 IU albutrepenonacog alfa (100 IU/ml after reconstitution) 1 vial with 2.5 ml water for injections
Estonian: 1 viaal pulbriga: 250 RÜ alfaalbutrepenonakogi (pärast manustamiskõlblikuks muutmist 100 RÜ/ml) 1 viaal 2,5 ml süsteveega
English: IDELVION 500 IU powder and solvent for solution for injection One vial contains nominally 500 IU of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP), (INN = albutrepenonacog alfa).
Estonian: Üks viaal sisaldab nominaalselt 500 RÜ IX faktorit albumiiniga ühendavat rekombinantset liitvalku (rIX FP) (INN = alfaalbutrepenonakog).
English: 500 IU per vial; after reconstitution with 2.5 ml of water for injections the solution contains 200 IU/ml of albutrepenonacog alfa.
Estonian: 500 RÜ viaali kohta; pärast manustamiskõlblikuks muutmist 2,5 ml süsteveega sisaldab lahus 200 RÜ/ml alfaalbutrepenonakogi.
English: 250 IU per vial; after reconstitution with 2.5 ml of water for injections the solution contains 100 IU/ml of albutrepenonacog alfa.
Estonian: 250 RÜ viaali kohta; pärast manustamiskõlblikuks muutmist 2,5 ml süsteveega sisaldab lahus 100 RÜ/ml alfaalbutrepenonakogi.
English: IDELVION 1000 IU powder and solvent for solution for injection Powder (1000 IU) in a 6 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Estonian: Pulber (1000 RÜ) 6 ml viaalis (I tüüpi klaas), millel on punnkork (kummist), kate (plastist) ja ümbris (alumiiniumist).
English: IDELVION 1000 IU powder and solvent for solution for injection One vial contains nominally 1000 IU of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP), (INN = albutrepenonacog alfa).
Estonian: Üks viaal sisaldab nominaalselt 1000 RÜ IX faktorit albumiiniga ühendavat rekombinantset liitvalku (rIX FP) (INN = alfaalbutrepenonakog).
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Powder vial 500 IU
Estonian: MINIMAALSED ANDMED, MIS PEAVAD OLEMA VÄIKESEL VAHETUL SISEPAKENDIL
English: IDELVION 250 IU powder for solution for injection Albutrepenonacog alfa
Estonian: IDELVION 250 RÜ süstelahuse pulber Alfaalbutrepenonakog Intravenoosne
English: For an incremental recovery of 1 IU/dl per 1 IU/kg, the dose is calculated as follows: Dose (IU) = body weight (kg) x desired factor IX increase (IU/dl) x 1 dl/kg
Estonian: Annus (RÜ) = kehamass (kg) x soovitud IX faktori sisalduse suurenemine (RÜ/dl) x 1 dl/kg
English: IDELVION 2000 IU powder for solution for injection Albutrepenonacog alfa
Estonian: IDELVION 2000 RÜ süstelahuse pulber Alfaalbutrepenonakog Intravenoosne
English: IDELVION 500 IU powder and solvent for solution for injection 1 vial with powder
Estonian: IDELVION 500 RÜ süstelahuse pulber ja lahusti: 1 viaal pulbriga
English: powder and solvent for solution for injection 1 vial with powder: 500 IU albutrepenonacog alfa (200 IU/ml after reconstitution) 1 vial with 2.5 ml water for injections
Estonian: 1 viaal pulbriga: 500 RÜ alfaalbutrepenonakogi (pärast manustamiskõlblikuks muutmist 200 RÜ/ml) 1 viaal 2,5 ml süsteveega
English: powder and solvent for solution for injection 1 vial with powder: 2000 IU albutrepenonacog alfa (400 IU/ml after reconstitution) 1 vial with 5 ml water for injections
Estonian: 1 viaal pulbriga: 2000 RÜ alfaalbutrepenonakogi (pärast manustamiskõlblikuks muutmist 400 RÜ/ml) 1 viaal 5 ml süsteveega
English: After reconstitution with 5 ml water for injections the solution contains 400 IU/ml of albutrepenonacog alfa.
Estonian: Pärast manustamiskõlblikuks muutmist 5 ml süsteveega sisaldab lahus 400 RÜ/ml alfaalbutrepenonakogi.
English: 1000 IU per vial; after reconstitution with 2.5 ml of water for injections the solution contains 400 IU/ml of albutrepenonacog alfa.
Estonian: 1000 RÜ viaali kohta; pärast manustamiskõlblikuks muutmist 2,5 ml süsteveega sisaldab lahus 400 RÜ/ml alfaalbutrepenonakogi.
English: Reconstitution and application
Estonian: Manustamiskõlblikuks muutmine ja kasutamine
English: IDELVION 1000 IU powder for solution for injection Albutrepenonacog alfa
Estonian: IDELVION 1000 RÜ süstelahuse pulber Alfaalbutrepenonakog Intravenoosne
English: IDELVION 500 IU powder and solvent for solution for injection Powder (500 IU) in a 6 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Estonian: Pulber (500 RÜ) 6 ml viaalis (I tüüpi klaas), millel on punnkork (kummist), kate (plastist) ja ümbris (alumiiniumist).
English: IDELVION 1000 IU powder and solvent for solution for injection 1 vial with powder
Estonian: IDELVION 1000 RÜ süstelahuse pulber ja lahusti: 1 viaal pulbriga
English: powder and solvent for solution for injection 1 vial with powder: 1000 IU albutrepenonacog alfa (400 IU/ml after reconstitution) 1 vial with 2.5 ml water for injections
Estonian: 1 viaal pulbriga: 1000 RÜ alfaalbutrepenonakogi (pärast manustamiskõlblikuks muutmist 400 RÜ/ml) 1 viaal 2,5 ml süsteveega
English: After reconstitution with 2.5 ml water for injections the solution contains 200 IU/ml of albutrepenonacog alfa.
Estonian: Pärast manustamiskõlblikuks muutmist 2,5 ml süsteveega sisaldab lahus 200 RÜ/ml alfaalbutrepenonakogi.
English: IDELVION 500 IU powder for solution for injection Albutrepenonacog alfa
Estonian: IDELVION 500 RÜ süstelahuse pulber Alfaalbutrepenonakog Intravenoosne
English: Cardiovascular events
Estonian: Kardiovaskulaarsed nähud
English: IDELVION 250 IU powder and solvent for solution for injection
Estonian: IDELVION 250 RÜ süstelahuse pulber ja lahusti
English: After reconstitution with 2.5 ml water for injections the solution contains 400 IU/ml of albutrepenonacog alfa.
Estonian: Pärast manustamiskõlblikuks muutmist 2,5 ml süsteveega sisaldab lahus 400 RÜ/ml alfaalbutrepenonakogi.
English: IDELVION 2000 IU powder and solvent for solution for injection Albutrepenonacog alfa
Estonian: IDELVION 2000 RÜ Süstelahuse pulber ja lahusti Alfaalbutrepenonakog
English: After reconstitution with 2.5 ml water for injections the solution contains 100 IU/ml of albutrepenonacog alfa.
Estonian: Pärast manustamiskõlblikuks muutmist 2,5 ml süsteveega sisaldab lahus 100 RÜ/ml alfaalbutrepenonakogi.
English: Formation of inhibitor to factor IX has been reported during factor replacement therapy with IDELVION in the treatment of haemophilia B. After repeated treatment with human coagulation factor IX products, patients should be monitored for the development of neutralising antibodies (inhibitors) that should be quantified in Bethesda Units (BU) using appropriate biological testing.
Estonian: Inhibiitori teket IX faktori suhtes on kirjeldatud faktorite asendusravi ajal IDELVION'iga Bhemofiilia ravis.
English: General Instructions
Estonian: Suur operatsioon
English: IDELVION 2000 IU powder and solvent for solution for injection
Estonian: IDELVION 2000 RÜ süstelahuse pulber ja lahusti
English: IDELVION 1000 IU powder and solvent for solution for injection
Estonian: IDELVION 1000 RÜ süstelahuse pulber ja lahusti
English: A peak level of 50 % of normal is required in a 20 kg patient with severe haemophilia B. The appropriate dose would be 20 kg x 50 IU/dl x 1 dl/kg = 1000 IUs.
Estonian: Sobiv annus on 20 kg x 50 RÜ/dl x 1 dl/kg = 1000 RÜ.
English: IDELVION 500 IU powder and solvent for solution for injection
Estonian: IDELVION 500 RÜ süstelahuse pulber ja lahusti
English: Pharmaceutical Form Route of administrationPackaging
Estonian: Pakendi iseloomustus
English: This may be painful and can occur at any time.
Estonian: See võib olla valulik ja tekkida igal ajal.
English: 2 - What you need to know before you take <product name> Warnings and precautions
Estonian: 2 - Mida on vaja teada enne <tootenime> võtmist Hoiatused ja ettevaatusabinõud
English: Adopted at the 28 November-1 December 2016 PRAC
Estonian: Vastu võetud riskihindamiskomitee 28. novembri - 1. detsembri 2016 koosolekul
English: During treatment, boys and adolescents may unexpectedly experience prolonged erections.
Estonian: Ravi ajal võib poistel ja noorukitel tekkida ootamatu pikaajaline erektsioon.
English: 4 - Possible side effects
Estonian: 4 - Võimalikud kõrvaltoimed
English: In case calciphylaxis is diagnosed, appropriate treatment should be started and consideration should be given to stopping treatment with <product name>.
Estonian: Kaltsifülaksia diagnoosi korral tuleb alustada asjakohast ravi ja kaaluda <tootenimi> ravi peatamist.
English: Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.
Estonian: Patsiendid, kellel tekivad ebanormaalselt pikaajalised või sagedased ja valulikud erektsioonid, peavad pöörduma kohe arsti poole.
English: Summary of product characteristics (both prescription and non-prescription) 4.8.
Estonian: Ravimi omaduste kokkuvõte (nii retsepti- kui ka käsimüügiravimid) 4.8.
English: The condition is mainly observed in patients with end-stage renal disease on dialysis or in patients with known risk factors such as protein C or S deficiency, hyperphosphataemia, hypercalcaemia or hypoalbuminaemia.
Estonian: Põhiliselt esineb see seisund patsientidel, kelle neeruhaigus on lõppstaadiumis ja kes saavad dialüüsi, või patsientidel, kellel esinevad teadaolevad riskifaktorid, nagu C- või S-valgu vaegus, hüperfosfateemia, hüperkaltseemia või hüpoalbumineemia.
English: It is important to contact your doctor straight away if your erection lasts for longer than 2 hours, particularly if this is painful.
Estonian: Kui erektsioon kestab kauem kui kaks tundi, tuleb kohe võtta ühendust arstiga, eriti kui erektsioon on valulik.
English: Frequency: common
Estonian: Esinemissagedus: sage
English: On rare occasions <product name> can cause serious skin conditions, including one called calciphylaxis that can start with a painful skin rash but can lead to serious complications.
Estonian: <Tootenimi> võib harvadel juhtudel põhjustada raskeid nahahaigusi, sh kaltsifülaksiat, mis võib alata valuliku nahalööbega ja viia raskete tüsistuste tekkimiseni.
English: Calciphylaxis is a rare syndrome of vascular calcification with cutaneous necrosis, associated with high mortality.
Estonian: Kaltsifülaksia on harva esinev vaskulaarse kaltsifikatsiooni ja nahanekroosi sündroom, mida seostatakse suure suremusega.
English: Methylphenidate - Priapism (EPITT no 18719)
Estonian: Metüülfenidaat - priapism (EPITT nr 18719)
English: Prolonged erections, sometimes painful, or an increased number of erections Frequency: not known
Estonian: Pikaajalised, mõnikord valulikud erektsioonid või erektsioonide sageduse suurenemine Esinemissagedus: teadmata
English: Summary of product characteristics (fluindione, phenindione)
Estonian: Ravimi omaduste kokkuvõte (fluindioon, fenindioon)
English: Package leaflet (both prescription and non-prescription) 4 - Possible side effects
Estonian: Pakendi infoleht (nii retsepti- kui ka käsimüügiravimid) 4 - Võimalikud kõrvaltoimed
English: Rare cases of calciphylaxis have been reported in patients taking vitamin K antagonists including <product name>, also in the absence of renal disease.
Estonian: Kaltsifülaksia harvadest juhtudest on teatatud patsientidel, kes võtavad K-vitamiini antagoniste, sealhulgas <tootenime>, ka neeruhaiguse puudumisel.
English: Rare cases of calciphylaxis have been reported in patients taking vitamin K antagonists, also in the absence of renal disease.
Estonian: Kaltsifülaksia harvadest juhtudest on teatatud patsientidel, kes võtavad K-vitamiini antagoniste, ka neeruhaiguse puudumisel.
English: Package leaflet (acenocoumarol, phenprocoumon) 4 - Possible side effects
Estonian: Pakendi infoleht (atsenokumarool, fenprokumoon) 4 - Võimalikud kõrvaltoimed
English: Proton pump inhibitors (PPIs): dexlansoprazole; esomeprazole; lansoprazole; omeprazole ; pantoprazole; rabeprazole - Gastric polyps (EPITT no 18725)
Estonian: Prootonpumba inhibiitorid (PPI): dekslansoprasool; esomeprasool; lansoprasool; omeprasool; pantoprasool; rabeprasool - maopolüübid (EPITT nr 18725)
English: Reproductive system and breast disorders Priapism, erection increased and prolonged erection Frequency: not known
Estonian: Reproduktiivse süsteemi ja rinnanäärme häired Priapism ehk sagedased ja pikaajalised erektsioonid Esinemissagedus: teadmata
English: Vildagliptin; Vildagliptin, metformin - Pemphigoid (EPITT no 18692)
Estonian: Vildagliptiin; vildagliptiin ja metformiin - pemfigoid (EPITT nr 18692)
English: Bullous or exfoliative Exfoliative and bullous skin lesions, including bullous pemphigoid Frequency: not known
Estonian: Villilised või eksfoliatiivsedEksfoliatiivsed ja villilised nahakahjustused, sealhulgas villiline pemfigoid Esinemissagedus: teadmata
English: Acenocoumarol; phenprocoumon; fluindione; phenindione - Calciphylaxis (EPITT no 18710)
Estonian: Atsenokumarool; fenprokumoon; fluindioon; fenindioonkaltsifülaksia (EPITT nr 18710)
English: Summary of product characteristics (acenocoumarol, phenprocoumon)
Estonian: Ravimi omaduste kokkuvõte (atsenokumarool, fenprokumoon)
English: Undesirable effects Skin and subcutaneous tissue disorders Frequency ‘not known': Calciphylaxis
Estonian: Esinemissagedus „teadmata”: kaltsifülaksia
English: Gastrointestinal disorders: Fundic gland polyps (benign) Frequency: common
Estonian: Seedetrakti häired: maopõhja näärmete polüübid (healoomulised) Esinemissagedus: sage
English: Benign polyps in the stomach
Estonian: Healoomulised maopolüübid
English: Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen.
Estonian: Metüülfenidaati sisaldavate ravimite kasutamisel, eriti metüülfenidaadi raviskeemi muutmisel, on teatatud pikaajalistest ja valulikest erektsioonidest.
English: Ginger
Estonian: Ingver
English: What is ginger?
Estonian: Mis on ingver?
English: Moreover, these intended uses do not require medical supervision.
Estonian: Peale selle ei nõua ettenähtud kasutamine meditsiinilist järelevalvet.
English: EMA/HMPC/296580/2012
Estonian: EMA/HMPC/296580/2012 Taimsete ravimite komitee (HMPC)
English: This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU.
Estonian: See tähendab, et on olemas bibliograafilised andmed teaduslike andmetega nende efektiivsuse ja ohutuse kohta sellel näidustusel, mis hõlmavad Euroopa Liidus vähemalt 10 aasta pikkust perioodi.
English: When serotonin attaches to these receptors it causes nausea and vomiting.
Estonian: Serotoniini seondumine nende retseptoritega põhjustab iiveldust ja oksendamist.
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Estonian: See tähendab, et kuigi nende taimsete ravimite kohta ei ole piisavalt kliiniliste uuringute andmeid, on nende efektiivsus tõenäoline ja ontõendeid, et neid on sel viisil ohutult kasutatud vähemalt 30 aastat (sealjuures Euroopa Liidus vähemalt 15 aastat).
English: Other information about ginger medicines
Estonian: Muu teave ingverit sisaldava ravimi kohta
English: The plant is cultivated or gathered to obtain the rhizome for medicinal use.
Estonian: Taime kasvatatakse või korjatakse, et saada selle risoomi meditsiiniliseks kasutamiseks.
English: The exact way ginger acts on the stomach and gut is not fully known, but it is thought to work by blocking certain receptors for the hormone 5HT3, known as serotonin, which are involved in the contraction of the smooth muscles inside the stomach and gut.
Estonian: Ingveri täpne toimemehhanism maos ja soolestikus ei ole täielikult teada, kuid arvatakse, et see blokeerib hormooni 5HT3 (serotoniini) teatud retseptorid, mis osalevad mao ja soolestiku silelihaste kontraktsioonis.
English: What evidence supports the use of ginger medicines?
Estonian: Millised tõendid toetavad ingverit sisaldava ravimi kasutamist?
English: For detailed information on the data assessed by the HMPC, see the HMPC assessment report.
Estonian: Üksikasjalikku teavet taimsete ravimite komitee poolt hinnatud andmete kohta vaadake komitee hinnanguraportist .
English: Further information on the HMPC assessment of ginger, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave ingverit sisaldava ravimi hinnangu kohta, sealhulgas komitee kokkuvõtte detailne kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the risks associated with ginger medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave ingverit sisaldava ravimiga kaasnevate riskide, sh ettevaatusabinõude kohta selle ohutuks kasutamiseks, on kirjas taime monograafias Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Common side effects (seen between 1 and 10 patients in 100) have been reported with ginger, mostly affecting the stomach and gut: stomach upset, eructation (belching), dyspepsia (heartburn) and nausea (feeling sick).
Estonian: Ingveri kohta teatatud sageli esinevad kõrvaltoimed (esinenud 1-10 patsiendil 100st) on enamasti seotud mao ja soolestikuga: seedehäired, röhitised, düspepsia (kõrvetised) ja iiveldus.
English: In its assessment, the HMPC considered a number of clinical studies with ginger, looking at its effectiveness in treating different conditions.
Estonian: Taimsete ravimite komitee uuris hinnanguraporti koostamisel mitmeid kliinilisi uuringuid, mis käsitlesid ingveri efektiivsust erinevate haigusseisundite ravis.
English: The results showed that ginger was more effective than placebo and as effective as other medicines in preventing motion sickness.
Estonian: Tulemused näitasid, et ingver on merehaiguse ennetamisel platseebost efektiivsem ja sama efektiivne kui muud ravimid.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing ginger.
Estonian: ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad ingverit sisaldavate taimsete ravimite müügilubade taotlusi.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of ginger.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb ingveri meditsiinilisi kasutusviise.
English: How does ginger work as a medicine?
Estonian: Kuidas ingver ravimina toimib?
English: Any applications for the licensing of medicines containing ginger have to be submitted to the national authorities responsible for medicinal products, which will assess the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Ingverit sisaldava ravimi müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimse ravimi müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslike järelduste kokkuvõtet.
English: Detailed instructions on how to take ginger-containing medicines and who can use them can be found in the package leaflet that comes with the medicine.
Estonian: Täpsed juhised, kuidas ingverit sisaldavaid ravimeid manustada ja kellele need on ette nähtud, on kirjas ravimi pakendi infolehes.
English: What are the risks associated with ginger medicines?
Estonian: Mis riskid kaasnevad ingverit sisaldava ravimiga?